【摘要】 目的：探讨卡介苗和表柔比星膀胱灌注预防非肌层浸润性膀胱癌（NMIBC）患者术后复发的临床疗效和安全性。方法：回顾性选取2019年1月～2020年5月在本院进行经尿道膀胱肿瘤切除术（TURBT）治疗的NMIBC患者200例作为研究对象。其中，接受卡介苗膀胱灌注治疗（卡介苗组）患者92例，接受表柔比星膀胱灌注治疗（表柔比星组）患者108例。比较两组术后6个月和12个月的复发情况，比较术后两组患者的生存质量、血清炎症因子[白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、可溶性细胞间黏附分子1(sICAM-1)]水平、血清肿瘤标志物[细胞角蛋白-19(CK-19)、CK-19片段抗原21-1(CYFRA21-1)]水平，观察并记录治疗相关不良反应的发生情况。结果：卡介苗组术后6个月和12个月的复发率分别为2.17%和7.61%，均低于表柔比星组的9.26%和16.67%(P<0.05)。术后12个月，卡介苗组生存质量评分高于表柔比星组（P<0.05）；卡介苗组血清IL-6、TNF-α、sICAM-1水平以及CK-19、CYFRA21-1水平均低于表柔比星组（P<0.05）；表柔比星组无发热发生，卡介苗组发热率为16.30%(P<0.05)，但患者均无需治疗即可恢复；两组血尿、尿痛、尿频/尿急发生率比较无统计学差异（P>0.05）。结论：卡介苗膀胱灌注治疗应用于TURBT术后NMIBC患者，可减轻炎症和降低肿瘤活力，预防肿瘤复发效果优于表柔比星膀胱灌注治疗，且具有一定的安全性。更多还原

【Abstract】 Objective:To investigate the clinical efficacy and safety of Bacillus Calmette-Guérin(BCG)vaccine and epirubicin in the prevention of postoperative recurrence after non-muscle invasive bladder cancer(NMIBC).Methods:A total of 200 patients with NMIBC who underwent transurethral resection of bladder tumor(TURBT) in our hospital from January 2019 to May 2020 were selected as research sujects.Among them,108 patients received epirubicin perfusion therapy(epirubicin group) and 92 patients received BCG perfusion therapy(BCG group).The recurrence was compared between the two groups at 6 months and 12 months after operation.The quality of life,levels of serum inflammatory factors [interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),soluble intercellular adhesion molecule-1(sICAM-1)],the levels of serum tumor markers [cyto keratin-19(CK-19),cytokeratin fragment 19 antigen 21-1(CYFRA21-1)] were compared between the two groups before and after treatment,and the occurrence of treatment-related adverse reaction was observed and recorded.Results:The recurrence rates of 6 months and 12 months after operation in BCG group were 2.17% and 7.61%,respectively,which were significantly lower than 9.26% and 16.67% in epirubicin group(P<0.05).12 months after operation,the quality of life score of BCG group was significantly higher than that of epirubicin group(P<0.05).The serum levels of IL-6,TNF-α,sICAM-1,CK-19 and CYFRA21-1 in BCG group were significantly lower than those in epirubicin group(P<0.05).There was no fever in epirubicin group,and the incidence of fever in BCG group was 16.30%(P<0.05),but no treatment was required for patients.There was no significant difference in the incidence of hematuria,urinary pain and urinary frequency/urgency between the two groups(P>0.05).Conclusion:BCG perfusion therapy for NMIBC patients after TURBT can reduce inflammation and tumor activity,and the prevention of recurrence is better than that of epirubicin,and has a certain safety.更多还原